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Spleen tyrosine kinase (Syk) is involved in cellular adhesion
and also in the activation and development of hematopoietic
cells. Syk activation induced by genomic rearrangement has
been linked to certain T-cell lymphomas, and Syk inhibitors
have been shown to prolong survival of patients with B-cell lin-
eagemalignancies. Syk is activated either by its interaction with
a double-phosphorylated immunoreceptor tyrosine-based acti-
vationmotif (pITAM),which induces rearrangements in the Syk
structure, or by the phosphorylation of specific tyrosine resi-
dues. In addition to its immunoreceptor function, Syk is acti-
vated downstream of integrin pathways, and integrins bind to
the same region in Syk as does pITAM. However, it is unknown
whether integrins and pITAM use the same mechanism to
activate Syk. Here, using purified Syk protein and fluorescence-
based enzyme assay we investigated whether interaction of the
integrin3 cytoplasmic domain with the Syk regulatory domain
causes changes in Syk activity similar to those induced by
pITAM peptides. We observed no direct Syk activation by solu-
ble integrin peptide, and integrin did not competewith pITAM-
induced activation even though at high concentrations, the
integrin cytoplasmic domain peptide competed with Syk’s
substrate. However, clustered integrin peptides induced Syk
activation, presumably via a transphosphorylation mecha-
nism. Moreover, the clustered integrins also activated a Syk
variant in which tyrosines were replaced with phenylalanine
(Y348F/Y352F), indicating that clustered integrin–induced
Syk activation involved other phosphorylation sites. In con-
clusion, integrin cytoplasmic domains do not directly induce
Syk conformational changes and do not activate Syk via the
same mechanism as pITAM.
Spleen tyrosine kinase (Syk) is a 72-kDa cytoplasmic signal-
ing protein discovered in bovine thymus (1) and forms a small
family of non-receptor tyrosine kinases with  chain-associated
protein kinase of 70 kDa (ZAP-70) (2). Knockout studies in
mouse show that Syk is required for B-cell differentiation (3).
Syk/mice are not viable because of severe perinatal hemor-
rhage due to lack of separation of lymphatic and venous vascu-
lature (4). Even though Syk/ stem cells can give rise to all
other hematopoietic cells than B-cells, Syk seems to have awide
function in many hematopoietic cell types, whereas the func-
tion of ZAP-70 is more restricted to T-cell and NK cells (2).
Syk has an important role in cancer. In hematological malig-
nancies Syk is mainly considered as a tumor promoter (5). A
chromosomal translocation has been found in T-cell leukemias
leading to fusion of interleukin 2 inducible T-cell kinase (ITK)
and SYK genes and to an aberrantly active Syk kinase (6). This
fusion has been validated as an oncogenic driver in a mouse
model (7). In many other hematological malignancies high Syk
activity has been detected (5), although, to our knowledge, no
human point mutations have been validated as oncogenic
driver mutations. Small molecule Syk inhibitors have been
designed and they were shown to prolong survival of patients
(8). At the moment, Syk inhibitors have not been approved for
clinical use because they are rather nonspecific and many side
effects are observed (9). In solid tumors, the role of Syk is less
clear than in hematological tissues. In many cases SYK expres-
sion is reduced during malignancy (e.g. see Ref. 10, reviewed in
Ref. 5). Many somatic mutations have been found in SYK genes
(cancer.sanger.ac.uk/cosmic)2 and epigenetic modification can
also be responsible for alterations in the expression (11). There
is some evidence that Syk can act as a tumor suppressor in
breast carcinomas because it reduces cell growth when re-ex-
pressed in a breast carcinoma cell line and tested in a xeno-
transplantation model (12).
Syk has a C-terminal tyrosine kinase domain and an N-ter-
minal regulatory domain formed by two Src homology 2 (SH2)3
domains connected by a flexible linker region called interdo-
main A (IA). This tandem SH2 region (tSH2) is connected to
the kinase domain via a second linker region called interdomain
B (IB) (13). The Syk activation mechanism is mostly under-
stood. The inactive kinase can interact through SH2 domains
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with phosphorylated immunoreceptor tyrosine-based activa-
tion motif (pITAM) associated with TCR, BCR, and FcR recep-
tors. Upon pITAM binding the tSH2 of Syk changes its orien-
tation in relationship to the kinase domain and allows kinase
activity (13). In addition, Syk is phosphorylated by Lyn and Lck
kinases and it also has an auto/transphosphorylation activity
that can lead to Syk activation independently frompITAM(14).
Considering that, an “OR gate switch” model for Syk activation
has been proposed (14, 15). Thismeans that an initial activation
by either pITAM binding, OR, by a phosphorylation event can
ultimately lead to full activity of the enzyme.
Inmany different biological processes ITAM-based receptor
signaling is concomitant with integrin signaling. The classical
example of this kind of collaboration is immunological synapse,
where both 2 integrins and TCR are required (16, 17). In neu-
trophils FcR signaling is linked to both integrin 2 and 3 func-
tion (18, 19). During platelet adhesion to damaged vascular cell
wall the collagen receptor GPVI–FcR complex works in con-
cert with 1 and 3 integrins (20). Clearly there are multiple
crossing points between pITAM/Syk and integrin signaling
pathways (reviewed in Ref. 2). There is also a direct interaction
between Syk and integrins: Syk interacts with integrin 1, 2,
and 3 cytoplasmic tails (21) and the interaction is mediated
mainly by N-SH2 domain and IA, whereas the C-SH2 has only
amarginal role in the binding (22). On the integrin side, the last
23 amino acids of 3 are sufficient for binding to Syk and dele-
tion of four C-terminal residues abolished the binding (21).
There are two tyrosine residues in the Syk interacting sequence
of integrin 3, but the interaction does not require integrin
phosphorylation. Rather, tyrosine-phosphorylated integrin
tails fail to interact with Syk (22). Although Syk has been shown
to be required for normal IIb3 integrin function in platelets
(23), a recent study has shown that integrin-induced Syk signal-
ing is independent on pITAM-induced Syk activation (24). In
this study, mutation of the Syk N-SH2 domain that prevented
phosphotyrosine binding blocked ITAM-dependent signaling
inmouse platelet, but did not alter integrin-dependent Syk acti-
vation (24).
Even though integrins were found to activate Syk signaling
more than two decades ago (25), it is still unclear how this
activation works. More specifically, can integrins activate Syk
via a similar conformational mechanism as pITAM? Are other
integrin-associated kinases required for the activation?Herewe
used in vitro kinetic fluorescence-based assay to study the effect
of the integrin 3 cytoplasmic domain peptide on the activity of
Syk. Our results show that soluble integrin peptides do not
directly activate Syk as pITAM peptide does. On the other
hand, we show that clustered integrin peptides can induce Syk
activation independently of other kinases, presumably via an
auto/transphosphorylation mechanism.
Results
Syk activitymeasurement using real-time fluorescence-based
assay
To study the regulation of Syk in vitro, we first characterized
the enzymatic properties of our purified full-length Syk protein
(Fig. 1). Tomonitor kinase activity, we used a substrate peptide
with SOX fluorophore ((S)-2-amino-N-(9-fluorenylmethyl-
oxycarbonyl)-3-[8-hydroxy-5-(N,N-dimethylsulfonamido)
quinoline-2-yl]propionic acid), whose fluorescence is modu-
lated by phosphorylation (13, 25–27). As shown before (14),
purified full-length Syk has low initial activity, which is
enhanced in the presence of ATP after a lag period (Fig. 2A).
This indicates that Syk has an intrinsic autophosphorylation or
transphosphorylation activity that can initiate protein activa-
tion by phosphorylation of specific tyrosines residues along the
structure (14). Because calculation of initial reaction velocity vi
is meaningless for the inactive or partially active enzyme, we
analyzed the kinetic parameters of the activated Syk that was
first incubated for 30minwithATP (Fig. 2,B–D). The datawere
fitted to the ternary model equation because it has been previ-
ously shown that Syk kinase substrate binding fits better with
ternary complex equation instead of the ping-pong model (28).
Km for SOX peptide was estimated to be 6  1 M and Km for
ATP was 29 3 M. The kcat, calculated considering the initial
velocity, was 22 3 min1.
Syk can be activated by pITAM but not by soluble integrin3
tails
The interaction between the integrin cytoplasmic tail and
Syk is mediated by tSH2 (22). We used surface plasmon reso-
nance (SPR) to confirm the interaction between tSH2 and the
integrin 3 cytoplasmic tail peptide. The integrin peptide was
coupled on the surface and increasing concentrations of tSH2
were injected on the sensor. The interaction had a fast,
concentration-dependent association phase and concentration-
independent dissociation phase (Fig. 3A). When the experimen-
tal data were fitted with Langmuir equation, the kinetic param-
eters were: kon  398  87 M1 s1, koff  (3.22  0.12) 103
s1, andKD (8.1 1.5) 106 M. Because the association phase
was very fast and the Langmuir model is mainly based on the
equilibrium levels, we also calculated the kinetic parameters
assuming a single binding site and using the association and
dissociation data only (Fig. 3, B–E) (see “Experimental proce-
dures”) (29, 30). With this method, the calculated kinetic
parameters were: kon 604 212 M1 s1, koff (2.68 0.20)
103 s1, and KD (4.44 1.55) 106 M. As expected, the koff
values were comparable, whereas the kon calculated with the
Langmuir model is half of the one calculated using first-rate
reaction equation. We reason that the kinetic model should in
this case be more accurate. On the other hand, the calculated
KD are comparable. Thus we consider that the KD value of
4.44 1.55 M is the best estimate from our data.
With 3 integrin/Syk interaction parameters in hand, we
next compared the effect of saturating concentrations of
pITAM and 3 integrin tail peptides on Syk activity. As
expected, 10 M pITAM significantly reduced the lag phase on
Syk activation. However, 30 M 3 tail peptide failed to do so
(Fig. 4A). When both peptides were present, the integrin pep-
tide did not change the effect of pITAM. When active Syk was
used in this assay in the presence of a saturating concentration
of SOX peptide neither pITAM nor integrin showed any effect
(Fig. 4B).
To further analyze the effect of integrin 3 cytoplasmic tail,
we investigated the possible activity modulation of active Syk.
Role of integrin cytoplasmic domain in Syk activation
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To assess the integrin effect on Km for the SOX peptide, the
ATP concentration was kept in saturating concentration and
different concentrations of SOX peptide ranging from 1.5 to 30
M were tested in the presence of integrin peptide (from 0 to
100 M). The same experiment was done to test the effect of
integrin onKm for ATP: SOXpeptide was in saturating concen-
tration and ATP was tested from 10 to 100 M. The double-
reciprocal plots (Fig. 4, C and D) are consistent with integrin
being a weak competitive inhibitor for the SOX peptide and
non-competitive inhibitor for ATP. However, the inhibition
was only observed at high integrin concentrations and the Ki
values could not be accurately calculated, possibly due to
poor solubility of the integrin peptide at 100 M concentra-
tion. This is all consistent with the integrin peptide contain-
ing two tyrosine residues and being able to act as a substrate
at high concentrations even though both tyrosines are not
preceded by negatively charged amino acids that are
required for good Syk substrates (31). Taken together, these
data show that the integrin 3 tail peptide does not directly
activate Syk, but it may be a substrate or competitive inhib-
itor at high concentrations.
Clustered integrin3 tails can enhance Syk activation
In contrast to our in vitro findings, assays with platelets or
cultured cells have shown that integrin ligation enhances Syk
activity (21, 25). This could either be mediated by other kinases
activated by integrin, such as Src family kinases, or by integrin
clustering. Tomimic integrin clustering in vitro, integrin 3 pep-
tide was coupled through the thiol group of the N-terminal cys-
teine on the assay plate at a high concentration. The clustered
integrin peptide caused a significant reduction of the lag phase of
Syk activity (Fig. 5A). Moreover, this effect was additive to that of
the soluble pITAMpeptide. This is consistentwith the hypothesis
that recruitment of Syk to integrin clusters will enhance its
transphosphorylation and thus lead to increased local activity
of the enzyme. As expected, clustered integrin did not have any
effect on the pre-activated Syk (Fig. 5B).
Sykmutant (Y348F/Y352F) can be activated by clustered
integrin3 tails
There are two tyrosine residues in the linker peptide of
C-SH2 and the kinase domain Syk (Tyr-348 and Tyr-353 in
human and Tyr-342 and Tyr-346 in mouse) that have been
reported to be themain phosphorylation sites required for acti-
vation of Syk via Src-family kinases (Fig. 1). To find out if these
residues are required for integrin clustering-induced activation
of Syk, we studied the activation of double mutant Syk (Y348F/
Y352F). Consistently with literature (13), this mutant has a low
basal activity that can be enhanced by the pITAM peptide (Fig.
6A). Surprisingly, Syk (Y348F/Y352F) activation was enhanced
by the clustered integrin in a similar way as that of wildtype Syk.
This suggests that Syk clustering by integrins causes transphos-
phorylation of Syk activation tyrosine residues other than Tyr-
348 and Tyr-352.
Discussion
Syk plays a crucial role in diverse types of cells and it is
involved in many biological processes. In this paper we have
Figure1.A, schematic representationof theSykkinasestructure.TheN-SH2andC-SH2aretheregulatorydomainsthatareconnectedtoeachother throughIA; they
are named tandemSH2 (tSH2) together. tSH2 are connected to kinase domain via IB. Tyrosines 348 and 352get phosphorylatedduringprotein activation and in this
studyweremutated to phenylalanine. B, SDS-PAGE of purified proteins. For each protein preparation 5g of proteinwas loaded on the gel.
Role of integrin cytoplasmic domain in Syk activation
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studied the consequences of integrin cytoplasmic domain bind-
ing to the enzymatic activity of Syk. Although it is well estab-
lished that pITAM containing receptors induce conforma-
tional changes in the regulatory domain of Syk and thus cause
direct activation of the kinase domain, it has not been studied
before whether integrin cytoplasmic domain peptides binding
to the same region as pITAM can do the same. We found that
soluble integrin peptides were not able to induce direct activa-
tion of Syk. Instead, integrin clustering could induce autophos-
phorylation of Syk and thus enhance its activation. These two
main findings are discussed below.
There are two pathways for the initialization of Syk activa-
tion. This property has been named the OR gate switch model
of Syk activation (15) meaning that Syk activation can either be
initialized via pITAM binding to tSH2 or via phosphorylation.
The molecular details of the pITAM/tSH2 interaction are
known (32). Briefly, the N-SH2 interacts with the C-terminal
pYXXL/I motif in ITAM receptor and the C-SH2 with the
N-terminal pYXXL/Imotif. The structures of two SH2s are very
similar and they contain a positively charged pocket to accept
the phosphotyrosine and a hydrophobic pocket to accommo-
date the leucine/isoleucine. It seems that for pITAM binding
both SH2s are needed even if the C-SH2 seems to be more
flexible and unstable compared with N-SH2 (32). As a conse-
quence of pITAM binding, the orientation of tSH2 in relation-
ship to the kinase domain changes and this releases the hinge
between two globes of the kinase leading to enhanced activity.
The other arm of the OR gate switchmodel implies that at least
Tyr-348, Tyr-352, and Tyr-630 can be phosphorylated directly
by Src family kinases such as Lyn, or auto/transphosphorylated
by Syk itself. This can also lead to full activation of the enzyme
independent of the interaction with pITAM (15).
Here our aim was to relate the OR gate switch model to
integrin-mediated Syk activation. Syk interacts with integrins
through tSH2 and, specifically, the N-SH2 and IA are mostly
involved, whereas the C-SH2 has a marginal contribution (22).
We confirmed the interaction between isolated tSH2 and integ-
rin3 cytoplasmic tail using SPR experiments; themeasuredKD
was 4.44  1.55 M, which indicates a medium-low affinity
binding. Woodside et al. (22) reported a higher affinity (KD 24
nM) using different peptides and different Syk preparations.
This discrepancy in the determined affinities should not affect
our enzyme activation assays aswe used 30Mconcentration of
integrin peptide, which should be close to saturating concen-
tration. We found that soluble integrin cytoplasmic domain
peptides did not change the lag phase of Syk activation in the
same way as pITAM peptides. Furthermore, integrin did not
inhibit pITAM-induced activation. This is consistent with
pITAMand integrins having distinct binding sites (21, 22). Our
Figure2.Kinetic characterizationofSykkinase.A, timecourse (min) of SOXpeptidephosphorylation (M) forbasal Syk (open circles) andactive Syk (squares).
Sykwas activated through incubationwith 100MATP for 30min at room temperature. Basal Syk and active Sykwere used at the same concentration of 17 nM;
basal Syk showed a5min lag phase, which was abolished in the active Sky. B, kinetic measurements of active Syk at different concentrations (2, 4, 8, and 17
nM). The inset shows the initial reaction speed (nM/min) calculated using linear regression fit from5 to 15min plotted against the active Syk concentration (nM).
The calculated kcat in this experiment was 22 3 min
1. C and D, Lineweaver-Burk plot generated from two-substrate analysis measurements of 1/vi versus
1/[ATP] (C) and 1/[SOX] (D). Experimental datawere fit with a ternary complex equation and the calculated Kmwas 6 1M for SOX peptide and 29 3M for
ATP.
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results thus indicate that integrins do not induce similar con-
formational changes in tSH2 as pITAM.
We also performed competition experiments using the 3
integrin cytoplasmic domain peptide with the active Syk kinase
and its ATP substrates and the SOX peptide. In this assay
integrin 3 peptide acted as a competitive inhibitor toward the
SOX peptide and showed characteristics of uncompetitive
inhibition toward the ATP. In both cases the inhibition was
observed at considerably higher concentrations than the
measured KD for the integrin binding to the tSH2 of Syk. Due
to technical problems related to low inhibitory activity,
we were not able to calculate Ki values using these data. The
simplest explanation of the observed effect is that the tyro-
sine-containing sequences in the integrin peptide can com-
pete with the substrate peptide. Similar behavior has been
observed earlier with ITAM peptides: even though they
do not contain the optimal Syk substrate recognition se-
quences, at high concentrations they reduce Syk activity
Figure 3. Interaction between tSH2 and integrin3 tail. A, SPR experiment where integrin3 tail peptidewas coupled on the surface (ligand) and different
concentrations of tSH2 (from 1.3 to 100 M) were injected (analyte). In the graph is plotted the variation of the RU in the time (s) for each tSH2 concentration
tested. Thearrow indicates the stopof the injection and, therefore, thebeginningof thedissociationphase.B, dRU/dt (variationof RU in time) is plotted against
RU (from 10 to 30 s of the association curve, see panel A). Solid lines correspond to the best linear regressions calculated for each tSH2 concentration. C,
calculation of association rate constant (kon) of the tSH2–integrin 3 tail peptide complex formation. Error bars are derived from linear regression analysis of
panel B in this figure (see “Experimental procedures”). D, variation of RU in the time (s) of the dissociation phase. The arrow indicates the end of injection as in
panel A. The dotted line corresponds to the part of dissociation curve that was not used for the determination of the dissociation rate constant (see panel E),
whereas the solid line indicates the part thatwas used. E, variation of ln(RU1/RUt) in time (s), the best linear fits are representedwith solid lines. RU1 indicates the
response units at the beginning of dissociation phase, and RUt indicates the response units at the time t. The slope of the linear regression corresponds to the
dissociation rate constant (koff) (see “Experimental procedures”).
Role of integrin cytoplasmic domain in Syk activation
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(14). Whether this phenomenon has any relevance to physi-
ological Syk function, remains unclear.
To study the possible contribution of integrin binding to the
other arm of the OR gate switch model, we mimicked integrin
clustering in vitro by coupling the 3 cytoplasmic domain pep-
tide via its N terminus to the surface of the enzymatic assay
plate. Integrin clustering is the basis of many, if not all, integrin
adhesion-induced signaling events (33). Integrin clustering is
partly mediated by extracellular ligands, partly by adhesome
components such as talin and kindlin, and partly by actin cyto-
skeleton (34). Integrin clusters are dynamic structures where
several components are exchanged rapidly (34, 35). We found
Figure 4. Effect of pITAM and integrin 3 tail on Syk wildtype activity. A, kinetic measurement of Basal Syk in the absence of peptide (open diamonds), in
presence of 30 M integrin 3 cytoplasmic tail peptide (diamonds), 10 M pITAM peptide (triangles), and a combination of both (open circles). The activity is
expressed in termsofnormalizedproduct formation in time (min); basal Sykwasusedat concentrationof 17nM. Error bars correspond to the standarddeviation
calculated from six different experiments. B,ANOVAof the 5-min time point in the experiment shown in panel A. The data indicate that the presence of soluble
pITAM activates the protein reducing the lag-phase of basal Syk. p value for basal Syk versus Syk pITAM and basal Syk versus Syk pITAM integrin were
both 0.0001. Comparing the basal Syk versus Syk  integrin and the Syk  pITAM versus Syk  integrin  pITAM with the ANOVA test resulted in
nonsignificant (ns)pvalues thus showing that the soluble integrin3 cytoplasmic tail peptidehadnoeffect.C, kineticmeasurementof active Syk in theabsence
of peptide (open diamonds), in the presence of 30 M integrin 3 cytoplasmic tail peptide (diamonds), 10 M pITAM peptide (triangles), and a combination of
both (open circles). The activity is expressed in terms of normalized product formation in time (min). Active Syk was used at 17 nM. D, the ANOVA of the 5-min
timepoint inpanel C; it resulted inanonsignificant (ns)pvalue suggesting that thepre-activatedSyk isnotmodulatedby thepresenceof eitherof twopeptides.
E and F, Lineweaver-Burk plots showing the competitive inhibition toward SOX peptide (E) and uncompetitive inhibition toward ATP (F) by the integrin 3
cytoplasmic tail. In each case 1/vi was plotted against 1/[SOX] (E) or 1/[ATP] (F). The experiments were carried out using active Syk at 4 nM.
Role of integrin cytoplasmic domain in Syk activation
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that clustered integrin peptides significantly reduced the lag
phase of Syk autoactivation. This effect was additive with the
pITAM-induced activation. We take this as evidence that
integrin clustering rapidly induces Syk transphosphorylation
by bringing several kinasemolecules in close proximity, leading
to increased local concentration (Fig. 7).We also found that the
Syk (Y438F/Y352F) mutant could be activated by clustered
integrins. This shows that in addition to the main regulatory
tyrosines 348 and 352, there are other residues that can be
transphosphorylated by the Syk itself and that activate the
kinase. Although it has been shown that activation loop
tyrosines 525 and 526 have little effect on Syk activity, it is well
established that the C-terminal tyrosines 630 and 631 can sta-
bilize the closed, inactive conformation of the enzyme (13, 36),
and thus phosphorylation of these could induce the activity of
even the Y438F/Y352F mutant. In mouse, Syk residues corre-
spondingtoTyr-630andTyr-631havebeenfoundtobeautophos-
phorylated or transphosphorylated (37).
In conclusion, enzyme kinetic studies presented here
imply that integrin cytoplasmic domain peptides do not
Figure 5. Effect of clustered integrin 3 cytoplasmic tails on Syk activation. A, time course (min) of the normalized product formation in the absence of
peptides (open diamonds) and in the presence of the integrin 3 cytoplasmic tail peptide coupled on the assay plate surface (diamonds), 10 M pITAM
(triangles), and combination of the twopeptides (open circles). Basal Sykwas used at 17 nM. Error bars correspond to the standard deviation calculated using six
different experiments. B,ANOVA of the 5-min time point in panel A. The experiment shows that surface-bound integrin peptide reduces the lag phase of basal
Syk; p value for basal Syk versus Syk  integrins was 0.0014 and was comparable with the p value for basal Syk versus Syk  pITAM, which was 0.0013. A
combination of two peptides further accelerated the process (p value0.0001). Integrin 3 cytoplasmic tail bound on the plate surface also has a synergic
effect in the presence of pITAM peptide, in fact comparing the Syk pITAM versus Syk pITAM integrins the ANOVA test gave a p value0.0001. C, time
course (min) of thenormalizedproduct formation in the absenceof peptides (opendiamonds) andpresenceof the integrin3 cytoplasmic tail peptide coupled
on the assay plate surface (diamonds), 10MpITAM (triangles), and a combination of two peptides (open circles). Active Sykwas used at 17 nM.D,ANOVAof the
experiment shown in panel C. p values were calculated using a ANOVA test including six separate experiments using the relative product formed at the 5-min
time point as described under “Experimental procedures.” p values were nonsignificant (ns).
Role of integrin cytoplasmic domain in Syk activation
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induce direct conformational changes in Syk and do not lead
to its activation with a similar mechanism as pITAM.
Instead, we propose that integrin clusters may increase the
local concentration of Syk and enhance its activity via
increased transphosphorylation.
Experimental procedures
Syk full-length expression and purification
Spleen tyrosine kinase (SYK) (EC 2.7.10.2) sequence cDNA
(UniProt ID: P43405) was obtained fromOrigene Technologies
Inc. (Rockville, MD) and a fragment containing amino acids
1–635 was expressed with the cleavable N-terminal His6 tag
(MSGSHHHHHHGSSGENLYFQ2SL, where 2 denotes a
tobacco etch virus (TEV) cleavage site) with pFastBac NT-
TOPO (Bac-To-Bac expression system, Invitrogen, Thermo
Fisher Scientific Inc.). The sequence of the expression
expression construct was verified by Sanger sequencing.
Spodoptera frugiperda (Sf9) insect cells were transfected
using Cellfectin II reagent (Thermo Fisher Scientific Inc.)
using the manufacturer’s protocol. Recombinant protein
Figure 6. Effect of pITAM and clustered integrin 3 tails on Syk Y348F/Y352F mutant activation. A, kinetic measurement of Syk mutant activity in the
absence of peptides (open diamonds), 30M integrin3 tail peptide (diamonds), 10MpITAM (triangles), and a combination of both peptides (open circles). Syk
FF was used at 17 nM concentration and the error bars are derived from the calculated standard deviation from six different experiments. B, ANOVA of the
30-min time point in panel A. Comparison of basal Syk FF versus Syk FF integrin and the Syk FF pITAM versus Syk FF integrin pITAM revealed that the
soluble integrin peptide does not activate Syk FF (p value non-significant, ns) in contrast to pITAM (p values0.0001). C, the same experiment described
in panel A, except the integrin 3 tail peptide, which was coupled on the plate surface. D, ANOVA of the 30-min time point in panel C. All p values were
0.0001.
Role of integrin cytoplasmic domain in Syk activation
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was expressed as described previously (38). Cells were har-
vested 72 h after infection (multiplicity of infection  1) by
centrifugation at 500 g and resuspended in cold lysis buffer
(50 mM sodium phosphate, 500 mM NaCl, 5 mM MgCl2, 0.1%
Nonidet P-40, 1 mM dithiothreitol (DTT), pH 8); PierceTM
Universal Nuclease for Cell lysis (ThermoFisher) 25 units/ml
and protease inhibitors tablet (cOmpleteTM Protease Inhib-
itor mixture, Sigma) were added separately to resuspended
cells. 5 ml of lysis buffer was used for grams of wetmass. Cells
were sonicated (10 times, 1-s pulse) in ice, and then the cells
suspension was clarified by centrifugation at 100,000 g for
1 h, 4 °C. Supernatant was loaded on a pre-equilibrated (50
mM sodium phosphate, 500 mM NaCl, 10 mM imidazole, pH
8) His Trap FF, 1-ml prepacked column (GE Heathcare Inc.)
with peristaltic pump at a flow rate of 0.5 ml/min, 4 °C. The
column was washed with binding buffer and protein was
eluted by stepwise imidazole gradient (10, 20, 50, 100, 250,
and 500 mM imidazole in 50 mM sodium phosphate, 500 mM
NaCl, pH 8). Fractions containing Syk were pooled and con-
centrated using Amicon Ultra 15-ml Centrifugal Filter,
30-kDa cutoff (Merck KGa). Protein was then loaded on
HiLoad 10/30 Superdex 200 column (GE Heathcare Inc.)
equilibrated with 10 mM Hepes, 150 mM NaCl, 10% glycerol,
10 mM methionine, 1 mM DTT, pH 7.5. Protein was concen-
trated to final concentration of 2 mg/ml; aliquots were fro-
zen in liquid nitrogen and stored in 80 °C.
Sykmutant (Y348F/Y352F)was obtainedwith aQuikChange
Multi-Site-directed Mutagenesis Kit (Agilent Technologies
Inc.) using wildtype Syk as template. Sf9 insect cells were har-
vested after 48 h infection (multiplicity of infection  3) and
lysed as described for Syk wildtype. Protein was purified as the
wildtype except that the affinity purified protein was incubated
with TEV overnight at 4 °C to remove the His6 tag. Protein was
then concentrated and loaded for gel filtration as described for
Syk wildtype. The final protein preparation was concentrated
to 1 mg/ml. The final protein sequence contains the Leu–Ser
sequence remaining from the TEV recognition site.
Tandem SH2 domains expression and purification
Tandem SH2 (amino acids 9–264) was cloned in plasmid
pGTvL1-SGC (Structural Genomics Consortium, University of
Oxford) using a ligation-independent method (39). The final
construct was sequence verified. The final protein sequence
contains a Ser–Met sequence that remained from the vector.
tSH2 were expressed using Escherichia coli BL21 gold cells
(Agilent Technologies Inc.) at 30 °C for 4 h with 0.4 mM isopro-
pyl -D-1-thiogalactopyranoside. The bacterial pellet was lysed
using a French press. The protein was captured with on a glu-
tathione-agarose column (Protino glutathione-agarose 4B,
Macherey-Nagel Gmbh) equilibrated with 20 mMTris, 100 mM
NaCl, 1 mM DTT, pH 8, and then eluted using same buffer
containing 50 mM glutathione. Glutathione S-transferase–
tSH2 complex was cut using TEV protease (Invitrogen), and
further purified by size exclusion chromatography with a
HiLoad 26/60 Superdex 75 column (GE Healthcare) in 20 mM
Tris, 100 mM NaCl, 1 mM DTT, pH 8. The final protein prepa-
rationwas concentrated using aAmiconUltra Centrifugal Fil-
ter, 30-kDa cut off to 30 mg/ml. Aliquots were frozen in liquid
nitrogen and stored at80 °C.
MS data acquisition and processing
Purified proteins were analyzed by mass spectrometry using
a Q-TOF type instrument (Waters Synapt G1) connected to an
Figure 7. A model of Syk activation mediated by clustered integrins. Integrin receptor subunits  and  are represented in blue and yellow, respectively.
ITAM containing receptor is in purple. Src family kinase is represented in pink; Lyn kinase is the Src kinase, which is mainly involved in the Syk activation
procedure. Syk is represented in two conformations (closed and open). The kinase domain is light green, whereas the SH2 domains are in dark green, black lines
indicate the linker regions. The small orange circles represent the phosphorylations along the Syk structure. A, combinedmodel of Syk activationmediated by
integrin and ITAM-containing receptors. Syk is recruitednear themembraneby the interactionwith integrin tail andphosphorylated ITAM. Syk is first activated
by interaction with pITAM through conformational rearrangement in the kinase structure. Then it can be phosphorylated by other kinases recruited via the
integrin pathway. Src-family kinasesmay be responsible for the phosphorylation of both ITAM receptor and Syk. B, Syk activationmodelmediated by integrin
clustering. Inactive Syk can interact with the integrin tail. The proximity effect enhances Syk trans/autophosphorylation activity leading to Syk activation.
Importantly, this pathway can occur independently of pITAM and Src family kinases.
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Acquity (Waters) UPLC chromatography system equipped
with a C4 reversed phase column (Waters BEH300 C4 1.7 m,
2.1 100mm). Protein samples were diluted 10-fold with 0.1%
trifluoroacetic acid (TFA) and 3-l aliquots were injected. The
eluents were 0.1% formic acid in water (A) and 0.1% formic acid
in acetonitrile (B). The gradientwas from3 to 60%Bover 8min.
The mass spectrometer was tuned for detection of proteins to
take 1-s lockmass (Leu encephalin) corrected scans in themass
range from 500 to 2000 m/z. Combined mass spectra for the
chromatographic peaks were deconvoluted using theMaxEnt 1
algorithm as part ofMasslynx (Waters). For tSH2 themeasured
molecular mass was 29,160 Da (expected 29,163 Da), for Syk
WT it was 74,443 Da (expected: 74,525 Da), and for Syk FF it
was 72,230 Da (expected 72,234 Da).
Surface plasmon resonance
The SPR experiment was done using a Biacore X instrument
(GEHealthcare Inc.). Integrin 3 cytoplasmic tail peptide (Uni-
Prot ID: P05106 CKFEEERARAKWDTANNPLYKEATSTFT-
NITYRGT, ProteoGenix, Schiltigheim, France) was coupled
onto CM5 (GE Healthcare) chips using thiol coupling. The
immobilization step was done at a 5 l/min flow rate with a
single flow cell. The carboxymethyl–dextran surface was acti-
vated using 1:1 ratio of 0.4 M 1-ethyl-3-(3-dimethylaminopro-
pyl)carbodiimide and 0.1 M N-hydroxysuccinimide for 10 min.
Then, 0.1 M ethylenediamine, 0.1 M sodium borate, pH 8.5, for 7
min, and 1 M ethanolamine, pH 7, for 10 min were injected. To
introduce thiol-reacting groups the surface was coupled with
50 mM Sulfo-GMBS (N-[-maleimidobutyryloxy]succinimide)
in 0.1 M sodium borate, pH 8.5, for 4 min. The peptide was
diluted using 10 mM Hepes, pH 7, at 50 g/ml and injected for
10min tomaximize the reactivitywith sulfo-GMBS. Finally, the
surface was blocked with 50 mM cysteine, 1 M NaCl, 0.1 M
sodium acetate, pH 4, for 4min. The experiment with tSH2was
carried outwith 10mMHepes, 150mMNaCl, pH7.5, as running
buffer and the flow rate of 10l/min using two flow cells. 2-Fold
dilutions of tSH2 were prepared in the running buffer starting
from 1.6 to 100 M. Each sample was injected for 6 min with a
delayed wash of 150 s. No surface regeneration was done
between injections. Each measurement was done at least three
times using different chips. The final resonance units (RU)were
obtained by subtracting the binding response obtained with
the nonfunctionalized sensor from that obtained from the
integrin 3 cytoplasmic tail peptide-coupled cell. The original
response curves were fit using a Langmuir model with Biacore
evaluation software 3.1 provided by themanufacturer. The data
were then analyzed following the method previously described
(29, 30). Briefly, to calculate the association rate kon of complex
integrin peptide–tSH2 the data from 10 to 30 s after injection
were used. First a plot ofdRU/dt (variation of RU in time) versus
RU was done, and then the slopes obtained from linear regres-
sions were replotted against the tSH2 concentrations used. The
kon is calculated based on equation,
SlopedRUdt vsRU kon C	 koff (Eq. 1)
where kon is the association constant, C is the protein concen-
tration injected, and koff is an estimation of the dissociation rate
of the complex. Because the dissociation rate is not dependent
on protein concentration it can be obtained using a first-rate
reaction equation,
InR1Rt koff t (Eq. 2)
whereR1 is the RU at the end of sample injection,Rt is the RU at
the time t, and koff is the dissociation constant. The Kd is equal
to koff/kon. Data analysis was performed using linear regression.
Fluorescence-based kinetic assay
Kinetic measurements of Syk were done using SOX fluores-
cent peptide (26, 27). The SOX peptide used was Ac-EEEEYIQ-
[DPro-Sox-G]-NH2 (Sigma) (28). The assay was performed in
SOXassay buffer (20mMHepes, 0.1mMEGTA, 1mMMgCl2, 10
M sodium orthovanadate, 5 mg/ml of BSA, 1 mM DTT, pH
7.15) in a final volume of 50 l. The fluorescence was detected
with VictorTM X4 2030 Multilabel Reader (PerkinElmer Life
Sciences) using 355 nm as excitation wavelength and 460 nm as
emission wavelength in 96-well black plates at 30 °C. Data were
collected every 30 s for at least 50 min. Each experiment was
repeated six times and each measurement within an experi-
ment was done in quadruplicate. Standard deviation was calcu-
lated using the data from six different experiments. Data were
analyzed using repeated measurements one-way ANOVA
(RM-ANOVA) followed by Tukey’s multiple comparison test
usingGraphPad Prism 7. To conduct the ANOVA analysis data
were first normalized to the highest measured product concen-
tration in the presence of pITAM and integrin and then arcsine
transformed.
Syk auto/transphosphorylation
Syk autophosphorylation was performed as previously de-
scribedwith somemodifications (14). Sykwildtype, 2.7M, was
incubated for 30 min at room temperature in the presence 100
M ATP, in a buffer containing 15 mM Hepes, 20 mM NaCl, 10
mM MgCl2, 1 mM EGTA, 10 M sodium orthovanadate, 10%
glycerol, pH 7.4, in a final volume of 2 ml. After incubation,
excess ATP was washed away using a PD10 desalting column
(GE Healthcare Inc.) using the same buffer and the protein was
concentrated to 0.2mg/ml withAmiconUltra Centrifugal Fil-
ter, 30 kDa cutoff.
Kinetic measurements of Syk activity and two-substrate
analysis
Syk kinetic measurements were performed following the
increase of the peptide fluorescence in the time as above
described in the presence of 10 M SOX peptide and 25 M
ATP. Basal Syk and active Syk were used at 17 nM, except for
two substrate analysis where active kinase was used at 4 nM; the
reaction was started by adding ATP as the last ingredient. Each
measurementwas done at least in triplicate; a blankwithout Syk
was recorded also and it was subtracted from the fluorescence
measured in the presence of the kinase. The two-substrate anal-
ysis was used to determine the Km for ATP and the SOX pep-
tide. Hence, in the case of Km for ATP, the ATP concentration
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was varied from 5 to 75 M in the presence of a constant con-
centration of SOXpeptide (from 1.5 to 30M). Likewise,Km for
SOXwas determined changing the SOX peptide concentration
from1.5 to 10M in the presence of a constant concentration of
ATP (from 5 to 75 M). The data were analyzed assuming that
the ternary complex model describes the Syk kinetic mecha-
nism (28),
v 
vmax[ATP][SOX]
[ATP][SOX]	 [ATP]Km
SOX	 [SOX]Km
ATPKm
ATPKa
SOX (Eq. 3)
where KmSOX and KmATPm are Michaelis-Menten constants of
SOX and ATP, respectively, and KaSOX is the association con-
stant of SOX for Syk.
Km for ATP and SOX peptide were calculated using the fol-
lowing equations derived fromEquation 3 assuming that one of
the two substrates is kept in a constant concentration,
1
vmax(app)

KmSOX
Vmax
1
[SOX]
	
1
Vmax
(Eq. 4)
1
vmax(app)

KmATP
Vmax
1
[ATP]
	
1
Vmax
(Eq. 5)
where Vmax(app) corresponds to the apparent rate of the reac-
tion in presence of a constant concentration of the other
substrate.
Effect of pITAM and integrin3 cytoplasmic tail on kinase
activation and on Syk activity
Basal and active Syk were tested in the presence of the
pITAM peptide from the CD3
 chain (UniProt ID: P07766,
NPDpYEPIRKGQRDLpYSGLNQR, ProteoGenix) and in the
presence of the integrin 3 cytoplasmic tail peptide. Both pep-
tideswere dissolved inwater and added to the reactionmixture.
The assay was performed as described above. pITAM peptide
and integrin 3 cytoplasmic tail peptide were used at concen-
trations of 10 and 30M, respectively; both basal and active Syk
were 17 nM. Differently, the inhibition analysis was done using
active Syk at 4 nM. Hence, to test the effect of the integrin 3
cytoplasmic tail peptide on Syk affinity for the SOXpeptide, the
ATP concentration was kept constant to 250 M (saturating
concentration), SOX was varied from 1 and 30 M, and the
integrin peptide from 0 to 100M. Similarly, to assess the integ-
rin peptide effect on Syk affinity for ATP, the SOX peptide
concentration was kept constant equal to 30 M (saturating
concentration) and ATP concentration ranged from 10 and
100 M.
Effect clustered integrin3 cytoplasmic tails on kinase
activation
Integrin 3 cytoplasmic tail peptide was coupled on the sur-
face of the assay plate through thiol coupling. PierceTM
maleimide-activated plates (Thermo Scientific) were used for
the coupling reaction following the methods suggested from
the manufacturer with minor changes. The plate was first
washed with washing buffer (0.1 M sodium phosphate, 0.15 M
NaCl, pH 7.2); peptide was diluted with coupling buffer (0.1 M
sodium phosphate, 0.15 M NaCl, 10 mM EGTA, pH 7.2) at 5 M
and incubated for 2 h on a plate shaker. Then, the not-reacted
groups were blocked with 10g/ml of cysteineHCl in coupling
buffer. Finally, the platewaswashed and dried by centrifugation
upside-down at 1000  g. The SOX peptide-based assay was
performed as described before except for the absence ofDTT in
the assay buffer.
Effect of pITAM and integrin3 cytoplasmic tail on Sykmutant
(Y348F/Y352F)
To assess the effect of pITAM and integrin 3 cytoplasmic
tail peptide on Syk mutant activity, the same procedure
described for Syk wildtype was used. Sykmutant was used at 17
nM and pITAM and integrin peptide at 10 and 30 M, respec-
tively. The same procedure was also used in the presence of the
integrin 3 cytoplasmic tail peptide coupled on the surface.
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